Human Immunodeficiency Virus (HIV) Diagnosis Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The diagnosis of human immunodeficiency virus (HIV) is a critical area within healthcare, with significant advancements anticipated in the coming years. As technology and awareness improve, the HIV diagnosis market is set for substantial growth, reflecting the increasing emphasis on early detection and innovative testing methods. Let's explore the current market outlook, key players, emerging trends, and segmentation details shaping this industry's future.

Projected Market Value and Growth Trajectory of the HIV Diagnosis Market
The HIV diagnosis market is poised for strong expansion, expected to reach a valuation of $7.4 billion by 2030. This represents a compound annual growth rate (CAGR) of 9.3%, highlighting robust demand over the forecast period. Several factors contribute to this growth, including the escalating need for early HIV detection, growing use of self-testing kits, advancements in point-of-care diagnostic technologies, and increased investments in infectious disease diagnostics. Additionally, there is a heightened focus on HIV prevention, routine monitoring, and integration of testing services, all of which are driving market expansion. Key market trends include a rising preference for rapid and point-of-care HIV tests, the popularity of home-based diagnostics, expanded availability of integrated testing with counseling, and a greater reliance on data-driven HIV surveillance.

The human immunodeficiency virus (hiv) diagnosis market size has grown rapidly in recent years. It will grow from $4.67 billion in 2025 to $5.19 billion in 2026 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to global prevalence of hiv infections, government-led hiv screening programs, increased availability of rapid diagnostic kits, expansion of diagnostic laboratory infrastructure, growing public health awareness initiatives.

Download a free sample of the human immunodeficiency virus (hiv) diagnosis market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15587&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Companies Leading the HIV Diagnosis Market
The HIV diagnosis space features several influential companies playing major roles, such as Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Becton dic*kinson and Company, Hologic Inc., bioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Bio-Techne Corporation, Alere Inc., Cepheid Inc., OraSure Technologies Inc., Advanced Instruments Inc., BBI Solutions, Chembio Diagnostic Systems Inc., BioLytical Laboratories Inc., Avioq Inc., Advanced Molecular Diagnostics, and Atila BioSystems Inc. These organizations drive innovation and maintain extensive portfolios within the HIV diagnostic arena.

Significant Acquisition Enhancing HIV Therapeutics Capabilities
In a notable development from July 2025, Future Pak, a US-based contract development and manufacturing organization (CDMO), acquired Theratechnologies Inc. for up to $254 million. This strategic acquisition aims to strengthen Future Pak's footprint in the HIV therapeutics market by incorporating Theratechnologies' marketed HIV drugs, including Trogarzo and Egrifta. Theratechnologies, headquartered in Canada, is recognized for its HIV-focused biopharmaceutical products, such as the monoclonal antibody Trogarzo (ibalizumab) and the lipodystrophy treatment Egrifta (tesamorelin). This deal is expected to enhance commercialization efforts and support future growth opportunities.

View the full human immunodeficiency virus (hiv) diagnosis market report:
https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-hiv-diagnosis-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovations and Trends Transforming the HIV Diagnosis Industry
Key players in the HIV diagnosis market are concentrating on developing long-acting, highly effective prevention and treatment options. They are also working to expand access through supportive reimbursement programs and pioneering clinical strategies designed to improve patient adherence and curb new infections. A prime example is Gilead Sciences, a US-based healthcare company, which in June 2025 gained FDA approval for Yeztugo (lenacapavir), the first twice-yearly injectable pre-exposure prophylaxis (PrEP) medication. Backed by Phase 3 PURPOSE 1 and PURPOSE 2 studies, Yeztugo demonstrated outstanding efficacy, with 99.9% or more participants remaining HIV-negative. This long-acting injectable aims to address challenges like adherence issues, stigma, and low awareness that limit traditional PrEP usage, offering a valuable tool for reducing new HIV cases across diverse populations.

Broad Access Initiatives Supporting HIV Prevention
To complement the launch of Yeztugo, Gilead is implementing wide-ranging access measures. These include partnerships with insurance providers, co-pay assistance for eligible patients, and free access programs for uninsured individuals. Such initiatives are crucial for ensuring that innovative HIV prevention options are available to those who need them most, supporting public health goals and improving overall outcomes.

A Detailed Look at the HIV Diagnosis Market Segments
The HIV diagnosis market can be categorized into several segments based on product, mode, and end user to provide a comprehensive overview:
1) Product Categories: Consumables, Instruments, Software, and Services
2) Modes of Diagnosis: Self-Test and Lab-Based Testing
3) End Users: Diagnostic Laboratories, Hospitals, and Research Institutions

Further subcategories under consumables include test kits-covering rapid HIV test kits and ELISA test kits-reagents, chemicals, sample collection devices such as blood collection tubes and lancets, test strips, control and calibration kits, and disposable gloves and safety equipment. Instrument subsegments encompass HIV diagnostic analyzers (including automated immunoassay analyzers), viral load testing equipment, CD4 count analyzers, point-of-care diagnostic devices, molecular diagnostic instruments like PCR machines, and electrochemical and optical detection instruments. Software options include HIV diagnosis data management software, electronic health record (EHR) integration tools, test result interpretation software, laboratory information management systems (LIMS), patient monitoring and tracking applications, and cloud-based HIV diagnostic reporting platforms. Service segments cover diagnostic testing, HIV testing support services such as counseling and education, diagnostic lab services, telemedicine and remote testing options, clinical trial services for diagnostic tests, and data analytics and interpretation services.

Regional Market Insights and Expansion Patterns
Although not detailed here, the HIV diagnosis market's growth is influenced by regional dynamics, with varying adoption rates, healthcare infrastructure, and funding models impacting overall expansion in different parts of the world. Understanding these nuances is essential for stakeholders aiming to optimize market penetration and address unmet diagnostic needs globally.

Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.